Literature DB >> 2785856

Murine interleukin-4 displays potent anti-tumor activity in vivo.

R I Tepper1, P K Pattengale, P Leder.   

Abstract

We have devised a sensitive means to assess the anti-tumor effect of cytokines that act via the mobilization of host-mediated defenses. This assay involves transfecting malignant cells to produce a specific cytokine (in this case, IL-4) and measuring the ability of transfectants to form tumors alone and when mixed with a variety of nontransfected tumor cells. In this way, we have identified a potent, non-cell autonomous, anti-tumor effect of IL-4 which is effective against a wide range of tumor cell types in vivo. The effect is reversed by anti-IL-4 antibody, correlates closely with levels of IL-4 production, and is evident in nu/nu mice. The anti-tumor effect seems to be mediated by an inflammatory infiltrate composed of eosinophils and macrophages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785856     DOI: 10.1016/0092-8674(89)90925-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  154 in total

1.  Immunotherapy of a murine T cell lymphoma localized to the brain.

Authors:  V K Ghant; N S Hiramoto; G Y Gillespie; D K Gauthier; R N Hiramoto
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Association of Interleukin-4 Polymorphisms With Breast Cancer in Taiwan.

Authors:  Chia-Wen Tsai; Chien-Chih Yu; DA-Tian Bau; Chin-Nan Chu; Yun-Chi Wang; Wen-Shin Chang; Zhi-Hong Wang; Liang-Chih Liu; Shao-Chun Wang; Cheng-Chieh Lin; Ting-Yuan Liu; Jan-Gowth Chang
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.

Authors:  B J Rollins; M E Sunday
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

4.  Cytokine immuno-gene therapy for treatment of brain tumors.

Authors:  Terry Lichtor; Roberta P Glick
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

5.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Ganciclovir mediated regression of rat brain tumors expressing the herpes simplex virus thymidine kinase imaged by magnetic resonance.

Authors:  A Maron; T Gustin; I Mottet; R Demeure; J N Octave
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G Spanakos; O E Tsitsilonis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

9.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Authors:  X Q Qin; N Tao; A Dergay; P Moy; S Fawell; A Davis; J M Wilson; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.

Authors:  Matthew T Wolf; Sudipto Ganguly; Tony L Wang; Christopher W Anderson; Kaitlyn Sadtler; Radhika Narain; Christopher Cherry; Alexis J Parrillo; Benjamin V Park; Guannan Wang; Fan Pan; Saraswati Sukumar; Drew M Pardoll; Jennifer H Elisseeff
Journal:  Sci Transl Med       Date:  2019-01-30       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.